MAT Growth (Pharmarack)
12.2%
+3.6pp vs IPM
Annual sales growth outperformed the Indian Pharma Market by 3.6 percentage points.
JAGSONPALPHARMACEUTICALS
Healthcare
30 Apr 2026
Jagsonpal Pharmaceuticals Ltd — Q4 FY26
Jagsonpal Pharmaceuticals reported a strong Q4 FY26 recovery with revenue of ₹64 crore (+10% YoY) and PAT of ₹9 crore (+31% YoY), driven by improved MR productivity and sharper brand focus in gynecology and dermatology.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Jagsonpal Pharmaceuticals reported a strong Q4 FY26 recovery with revenue of ₹64 crore (+10% YoY) and PAT of ₹9 crore (+31% YoY), driven by improved MR productivity and sharper brand focus in gynecology and dermatology. The company outperformed the IPM with 14.2% growth in Q4 (vs IPM ~10.5%) and 12.2% MAT growth (vs IPM ~8.6%). Management reiterated its target of growing at 1.5x IPM (implying 12-15% revenue growth) and expects margin stability. A ₹40 crore buyback and 200% dividend (including 75% special) underscore capital discipline. Key risk: cost pressures from Middle East disruptions on packaging and raw materials, though management believes impact on profitability will be limited.
Key Numbers
Q4 Growth (Pharmarack)
14.2%
+3.7pp vs IPM
Quarterly growth accelerated to 14.2% against IPM growth of ~10.5%.
Cash Position
₹190 Cr
Flat vs prior year
Strong cash balance of over ₹190 crore at year-end, enabling buyback and dividend.
Volume Growth (Pharmarack)
2%
+1pp vs IPM
Volume growth of 2% vs IPM's ~1%, indicating market share gains.
Management Guidance
Revenue growth target of 1.5x IPM
Management targets growing at 1.5 times the Indian Pharma Market growth, implying 12-15% revenue growth based on current IPM trends.
Management guidance growthNew product launches: 9-10 in FY27
Plans to launch 9-10 new products or brand extensions in FY27, with half being brand extensions and half new products in core therapies.
Management guidance growthNo increase in MR headcount
Management stated they do not intend to increase MR numbers, with growth driven entirely by productivity improvements.
Management guidance otherKey Risks
Cost pressure from Middle East disruptions
Packaging material costs are rising due to Middle East tensions, and CMO partners may pass on cost increases, though management expects limited profitability impact.
medium · analyst_questionExecution risk in new product launches
Management acknowledged that new product establishment takes over a year for prescription pickup, and some products may not achieve expected market traction.
medium · management_commentaryConcentration risk in top 10 brands
Top 10 brands constitute 58-60% of sales; any slowdown in these brands could materially impact overall growth, though management sees balanced portfolio.
low · data_observationNotable Quotes
We have done the walk the talk. We have given you a guidance that we'll be looking at beating the market growth and that is what our objective has been.
We are certainly targeting 1.5x of the pharma industry growth. Currently the pharma industry is trending anywhere between 6-7% to 8-9%.
We are not adding any new MR. But we are trying to see whether organically from the same geography we are able to extract more and thereby conserving our cost as well.
Frequently Asked Questions
What was Jagsonpal Pharmaceuticals's revenue in Q4 FY26?
Jagsonpal Pharmaceuticals reported revenue of ₹64 Cr in Q4 FY26, representing a +10% change compared to the same quarter last year.
What guidance did Jagsonpal Pharmaceuticals management give for FY27?
Revenue growth target of 1.5x IPM: Management targets growing at 1.5 times the Indian Pharma Market growth, implying 12-15% revenue growth based on current IPM trends. New product launches: 9-10 in FY27: Plans to launch 9-10 new products or brand extensions in FY27, with half being brand extensions and half new products in core therapies. No increase in MR headcount: Management stated they do not intend to increase MR numbers, with growth driven entirely by productivity improvements.
What are the key risks for Jagsonpal Pharmaceuticals in FY27?
Key risks include Cost pressure from Middle East disruptions — Packaging material costs are rising due to Middle East tensions, and CMO partners may pass on cost increases, though management expects limited profitability impact.; Execution risk in new product launches — Management acknowledged that new product establishment takes over a year for prescription pickup, and some products may not achieve expected market traction.; Concentration risk in top 10 brands — Top 10 brands constitute 58-60% of sales; any slowdown in these brands could materially impact overall growth, though management sees balanced portfolio..
Did Jagsonpal Pharmaceuticals meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Jagsonpal Pharmaceuticals Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.